Abstract
Background: The World Health Organization recommends use of killed oral cholera vaccines (kOCV) as part of cholera prevention and control, but data on the duration of effectiveness of the most widely available vaccine, Euvichol® is limited. We evaluated the effectiveness of Euvichol® 5 years after a kOCV campaign conducted in Haiti in 2017.Methods: We undertook a frequency-matched case-control study in Mirebalais, Haiti from October 2022 to February 2023 as a cholera outbreak resurged. Cases were patients with acute watery diarrhea, had a stool sample positive for V. cholerae by polymerase chain reaction, and had been eligible for kOCV during the 2017 campaign. Cases were frequency-matched with community controls by age group and neighborhood. Participants reported sociodemographics, risk factors, and vaccination status. We used adjusted logistic regression analyses to estimate vaccine effectiveness (VE) of at least one kOCV dose versus none.Findings: We analyzed 93 cases and 135 controls. 22% of the cases and 51% of the controls self-reported vaccination. Receiving Euvichol in 2017 was associated with a 5-year adjusted VE of 78% (95% CI: 57%-89%, p<0.0001).Interpretation: Euvichol® effectively protected against cholera in Haiti, 5 years after a vaccination campaign. This has important implications for public health planning, especially consideration of re-dosing schedules and comparative effectiveness analyses.